Starpharma Holdings Limited · ASX:SPL
Starpharma — OTCQX Virtual Life Sciences Investor Forum 2021
33 slides from Starpharma's conference presentation, Jun 24, 2021
Slide 1: Starpharma to present at Virtual Life Sciences Investor Forum
Starpharma to present at Virtual Life Sciences Investor Forum Melbourne, Australia; 24 June 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that a presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 24 June 2021 (US ET) as part of OTCQX’s Virtual Life Sciences Investor Fo
Slide 2: Forward Looking Statements
Forward Looking Statements This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “
Slide 3: OTCQX Virtual Investor Conference
ASX:SPL OTC:SPHRY OTCQX Virtual Investor Conference 24 June 2021 DR JACKIE FAIRLEY CEO 1
Slide 4: Important notice and disclaimer
Important notice and disclaimer This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimate
Slide 5: Starpharma's dendrimer platform delivers significant optionality
Starpharma’s dendrimer platform delivers significant optionality with multiple potential revenue streams, valuable products & clinical-stage assets Key Investment Data Through innovative research and development, Starpharma is creating therapies which have the potential to improve patient health wor
Slide 6: Starpharma's portfolio
Starpharma’s portfolio High-value assets including VivaGel® products on market, SPL7013 antivirals and multiple DEP® clinical assets Extensive & growing pipeline of Multiple clinical stage assets Multiple approved products proprietary assets APPROVED PRODUCTS FURTHER APPROVALS INTERNAL & PARTNERED I
Slide 7: VIRALEZE antiviral nasal spray is virucidal, inactivating >99.9% of SARS-CoV-2
VIRALEZE™- antiviral nasal spray is virucidal, inactivating >99.9% of SARS-CoV-2 (the coronavirus that causes COVID-19) • Broad-spectrum antiviral nasal spray containing 1% w/w astodrimer sodium (SPL7013), shown in laboratory studies to inactivate respiratory viruses, including >99.9% of coronavirus
Slide 8: The science behind VIRALEZE
The science behind VIRALEZE™ SPL7013 has • Extensive research has been conducted at the Scripps Research Institute in the US and demonstrated is published in the prestigious, peer reviewed scientific journal, Antiviral Research. potent activity in influenza, • A 1% w/w concentration of astodrimer so
Slide 9: VIRALEZE active has potent virucidal activity against SARS-CoV-2 variants of concern
VIRALEZE™ active (SPL7013) has been shown to have potent virucidal activity (>99%) against multiple SARS-CoV-2 ‘Variants of Concern’ “We know this virus knows no geographic borders and addressing this reality is more pressing than ever before, given the rapid proliferation of Covid-19 variants that
Slide 10: VIRALEZE Harlequins partnership illustrates sporting and occupational opportunities
VIRALEZE™ Harlequins partnership illustrates potential sporting and occupational opportunities for the product Iconic UK rugby team Harlequins recently partnered with Given its broad spectrum of activity in SARS CoV-2 VIRALEZE™ strains and variants VIRALEZE™ could prove to be particularly useful in
Slide 11: VIRALEZE market research shows a high level of consumer interest
VIRALEZE™- market research shows a high level of consumer interest “Of course, I would (be interested in a spray “So I think wearing gloves and a mask reduces available for prevention), yeah!” the risk, but not enough… this would reduce it even more just an additional barrier” Consumer research, Nov
Slide 12: DEP is a technology platform with multiple commercial opportunities
DEP® is a technology platform with multiple commercial opportunities in oncology and beyond • Antiviral NON-ONCOLOGY • Anti-infective • Endocrinology • Franchise extension • Generic differentiation CHEMOTHERAPEUTICS • New Chemical Entities • Combinations including DEP® immuno-oncology PLATFORM RADIO
Slide 13: DEP docetaxel benefits
DEP® benefits Starpharma’s DEP® platform conveys product benefits and enhances the commercial value of a wide range of drugs and therapeutic areas DEP® BENEFITS* 3 x w e e k ly in je c t io n s DEP® platform: Improved Efficacy ) 1400 3 M e a n T u m o u r V o lu m e (m m 1200 Reproducible results wi
Slide 14: DEP partnering creates significant value and optionality
DEP® partnering creates significant value and optionality Starpharma’s DEP® platform enhances the commercial and therapeutic value of a wide range of drugs, creating multiple potential revenue streams and significant IP leverage DEP® platform allows for multiple partnerships AstraZeneca’s novel DEP®
Slide 15: DEP internal: multiple clinical-stage assets with high commercial value potential
DEP® internal Multiple clinical-stage assets with high commercial value potential Create value through clinical proof-of- COMMERCIAL License following proof-of-concept Utilise accelerated development / regulatory OBJECTIVE concept in one or more cancer types clinical data; platform validation pathwa
Slide 16: DEP docetaxel: phase 2 trial ongoing, encouraging efficacy signals
DEP® docetaxel: phase 2 trial ongoing, encouraging efficacy signals Enhanced version of docetaxel (Taxotere®) – widely used for breast, lung & prostate cancer Trial status: Phase 2 trial ongoing, >44 patients recruited The same tumour targeting observed with DEP® in animal studies has been replicate
Slide 17: DEP docetaxel: clinical case studies
DEP® docetaxel: clinical case studies DEP® docetaxel trial case study: 72-year-old woman: DEP® docetaxel trial case study: 66-year-old man: extensive intrahepatic cholangiocarcinoma, an often-fatal stage IV oesophageal cancer with liver metastases cancer that affects the bile ducts Oesophageal cance
Slide 18: DEP cabazitaxel: phase 2 trial ongoing, encouraging efficacy signals
DEP® cabazitaxel: phase 2 trial ongoing, encouraging efficacy signals Enhanced version of leading prostate cancer drug cabazitaxel (Jevtana®) Trial status: Phase 2, ongoing, >38 patients recruited Prostate cancer patient experienced >47 weeks Efficacy signals Prostate, ovarian, gastro-oesophageal, c
Slide 19: DEP cabazitaxel: clinical case studies
DEP® cabazitaxel: clinical case studies DEP® cabazitaxel trial case study: 65-year-old man with late- DEP® cabazitaxel trial case study: 60-year-old woman with stage (metastatic) gastro-oesophageal cancer advanced (metastatic) ovarian cancer Oesophageal cancer is the seventh most common cause of Ova
Slide 20: DEP irinotecan: phase 2 trial underway, encouraging efficacy signals
DEP® irinotecan: phase 2 trial underway, encouraging efficacy signals Enhanced version of irinotecan (Camptosar®) - predominantly used for colorectal cancer Trial status: Phase 2, ongoing, >47 patients recruited Results from DEP® irinotecan phase 1 trial: • 7 patients were enrolled and received up t
Slide 21: DEP irinotecan: clinical case studies
DEP® irinotecan: clinical case studies DEP® irinotecan trial case study: 55-year old woman with DEP® irinotecan trial case study: 45-year old woman with stage heavily pre-treated metastatic ovarian cancer, which has a IV breast cancer with extensive liver metastases particularly poor prognosis. Brea
Slide 22: DEP Antibody Drug Conjugates further build the value of the platform
DEP® Antibody Drug Conjugates (ADCs) further build the value of the platform Starpharma’s DEP® technology provides enhanced therapeutic benefits to ADCs including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches DEP® DEP® HER-2 ADC
Slide 23: DEP is a valuable tool for radiodiagnostics and radiotherapeutics
DEP® radiotheranostics DEP® is a valuable tool for radiodiagnostics and radiotherapeutics Starpharma has developed multiple novel radiotheranostic candidates DEP® radiopharmaceutical conjugates have the potential to minimise off target toxicity and enhance efficacy when used alone or in combination
Slide 24: DEP - a valuable tool for radiodiagnostics and radiotherapeutics
DEP® - a valuable tool for radiodiagnostics and radiotherapeutics Starpharma has developed multiple novel radiotheranostic candidates DEP® radiopharmaceutical conjugates have the potential to minimise off target toxicity and enhance efficacy when used alone or in combination with other therapeutic a
Slide 25: VivaGel BV - a breakthrough product for the management of BV
VivaGel® BV - a breakthrough product for the management of BV – the most common vaginal infection worldwide, affecting 1 in 3 women Bacterial vaginosis or BV is caused by an imbalance of naturally occurring normal bacterial vaginal flora (an overgrowth of pathogenic bacteria) BV can lead to a range
Slide 26: VivaGel BV licensed in >160 countries
VivaGel® BV licensed in >160 countries around the world Global market for NORTH EUROPE BV treatment est. MIDDLE EAST AMERICA to be US$750M ON MARKET and prevention est. to be US$1B annually AFRICA ASIA ON MARKET ON MARKET Launched in the UK, Europe, Asia, CY21: South Africa, Pre-launch Australia & N
Slide 27: Positive experiences with VivaGel BV - patients and healthcare professionals
Positive experiences with VivaGel® BV - patients and healthcare professionals “Amazing, amazing, amazing…within two days I “The pharmacist and the girls noticed the BV clearing up.” absolutely love the new symptom UK customer review checker!! They all think that it will make life much easier when it
Slide 28: Marketing campaigns for VivaGel BV in multiple regions
Marketing campaigns for VivaGel® BV in multiple regions After 18 months on market, Award winning 79% of Pharmacists are campaign aware & 53% of most often recommend Fleurstat. FLEURSTAT BVGEL RANKS AS #1 TOPICAL BV TREATMENT IN AUSTRALIA Source: ACA Research Fleurstat Brand Tracking Study – in field
Slide 29: VivaGel BV regulatory progress
VivaGel® BV regulatory progress Approved in >45 countries with multiple other submissions underway Submitted / Approved submissions Licensed region underway UK Europe Asian countries Australia & New Zealand African & Middle Eastern countries Latin American countries US US regulator
Slide 30: Starpharma's Commitment to ESG
Starpharma’s Commitment to ESG: The very nature of Starpharma's products affords the opportunity of changing lives for the better • Through innovative research and development, Starpharma’s supplier code Starpharma and its partners are creating therapies includes a wide range of business practices t
Slide 31: Financial summary: strong balance sheet with $64.3M cash
Financial summary Strong balance sheet with $64.3M cash (at 31-Mar-21) 1H FY21 1H FY20 FY20 Key Financial Data A$M A$M A$M Loss for the period (10.4) (5.9) (14.7) Net operating cash outflows (5.4) (5.2) (10.8) Net cash burn (excluding capital raise)1 (6.7) (5.4) (11.2) Cash as at 31 March 2021 is $6
Slide 32: Outlook
Outlook VIRALEZE™ / VIVAGEL® / SPL7013 • Further roll-out of VIRALEZE™ Antiviral Nasal Spray • Further VIRALEZE™ registrations and launches; commercial arrangements LEVERAGE EXISTING APPROVALS • Continued testing of SPL7013 against SARS-CoV-2 variants and other viruses • Commercial roll-out of VivaG
Slide 33: For investor relations enquiries contact
FOR INVESTOR RELATIONS ENQUIRIES CONTACT: Dr Jackie Fairley, CEO +61 3 8532 2704 investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford Vic 3067 WWW.STARPHARMA.COM ASX:SPL OTC:SPHRY 31
Starpharma Holdings — OTCQX Virtual Life Sciences Investor Forum 2021 on 6ix